智通财经APP讯，浙江东方(600120.SH)发布公告，近日，公司收到中国证券监督管理委员会(简称"中国 证监会")核发的《关于同意浙江东方金融控股集团股份有限公司向专业投资者公开发行公司债券注册的 批复》(证监许可〔2025〕2419)号，同意公司向专业投资者公开发行面值总额不超过60亿元公司债券的 注册申请。 ...

浙江东方（600120）(600120.SH)发布公告，近日，公司收到中国证券监督管理委员会(简称"中国证监 会")核发的《关于同意浙江东方金融控股集团股份有限公司向专业投资者公开发行公司债券注册的批 复》(证监许可〔2025〕2419)号，同意公司向专业投资者公开发行面值总额不超过60亿元公司债券的注 册申请。 ...

（编辑 楚丽君） 证券日报网讯 11月11日晚间，浙江东方发布公告称，为进一步拓宽融资渠道并降低融资成本，优化资 产负债结构，提升运营效率，公司控股子公司浙江国金融资租赁股份有限公司拟申请注册发行资产支持 证券（ABS）。 ...

| 股票代码：600120 | 证券简称：浙江东方 | | | 编号：2025-058 | | --- | --- | --- | --- | --- | | 债券代码：138898.SH | 债券简称：23 | 东方 | 01 | | | 债券代码：240620.SH | 债券简称：24 | 东方 | 01 | | | 债券代码：241264.SH | 债券简称：24 | 东方 | K1 | | | 债券代码：241781.SH | 债券简称：24 | 东方 | 03 | | （一）原始权益人：国金租赁，主体信用评级 AA+。 （二）基础资产：国金租赁享有的融资租赁合同项下的租金请求权和其他权 利及其附属担保权益。 （四）发行规模：本次资产支持证券申请注册发行，总额度不超过 40 亿元， 一次注册、分期发行。 （五）发行期限：单期存续期不超过 3 年。 浙江东方金融控股集团股份有限公司 关于控股子公司拟注册发行资产支持证券的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步拓宽融资渠道并降低融资成本，优化资产负债 ...

南方中证1000ETF（512100）成立日期2016年9月29日，最新规模766.3亿。今年以来收益28.45%，同类 排名1974/4216；近一年收益19.26%，同类排名2173/3922；成立以来收益13.67%。 南方中证1000ETF（512100）基金经理为崔蕾。 11月11日，浙江东方涨5.33%，截至发稿，报7.12元/股，成交9.27亿元，换手率3.91%，总市值243.18亿 元。 资料显示，浙江东方金融控股集团股份有限公司位于浙江省杭州市上城区香樟街39号国贸金融大厦31- 33层，成立日期1994年10月26日，上市日期1997年12月1日，公司主营业务涉及商贸流通(涵盖内外贸业 务)、房地产经营、服装生产实业以及类金融投资与服务;信托、期货和保险在内的广泛的金融行业。主 营业务收入构成为：期货业务80.29%，融资租赁7.81%，保险业务5.07%，信托业务3.32%，其他 3.13%，投资业务0.64%。 从浙江东方十大流通股东角度 数据显示，南方基金旗下1只基金位居浙江东方十大流通股东。南方中证1000ETF（512100）三季度减 持18.27万股，持有股数1874.6万股 ...

Market Overview - The diversified financial sector experienced a decline of 0.53% on November 7, with Zhejiang Dongfang leading the drop [1] - The Shanghai Composite Index closed at 3997.56, down 0.25%, while the Shenzhen Component Index closed at 13404.06, down 0.36% [1] Stock Performance - Notable gainers in the diversified financial sector included: - Electric Investment and Financing (Code: 000958) with a closing price of 6.96, up 2.81% [1] - Jiuding Investment (Code: 600053) with a closing price of 20.94, up 2.25% [1] - Haide Co., Ltd. (Code: 000567) with a closing price of 7.87, up 1.81% [1] - Conversely, Zhejiang Dongfang (Code: 600120) saw a significant decline of 3.57%, closing at 6.76 [2] Trading Volume and Capital Flow - The diversified financial sector saw a net outflow of 430 million yuan from main funds, while retail investors contributed a net inflow of 346 million yuan [2] - The trading volume for Electric Investment and Financing was 841,100 shares, with a transaction value of 58.2 million yuan [1] Individual Stock Capital Flow - Electric Investment and Financing had a main fund net inflow of 49.82 million yuan, while retail investors had a net outflow of 38.01 million yuan [3] - Jiuding Investment recorded a main fund net inflow of 40.05 million yuan, with retail investors experiencing a net outflow of 38.90 million yuan [3] - Zhejiang Dongfang had a significant main fund net outflow of 9.77 million yuan, indicating a bearish sentiment [2][3]

| 股票代码：600120 | 证券简称：浙江东方 | | | 编号：2025-057 | | --- | --- | --- | --- | --- | | 债券代码：138898.SH | 债券简称：23 | 东方 | 01 | | | 债券代码：240620.SH | 债券简称：24 | 东方 | 01 | | | 债券代码：241264.SH | 债券简称：24 | 东方 | K1 | | | 债券代码：241781.SH | 债券简称：24 | 东方 | 03 | | 浙江东方金融控股集团股份有限公司 关于为下属公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ● 被担保人名称： 1、东方嘉富人寿保险有限公司（简称"东方嘉富人寿"） 2、浙江济海贸易发展有限公司（简称"浙江济海"） 3、浙江东方集团供应链管理有限公司（简称"东方供应链"） 4、舟山济海能源有限公司（简称"舟山济海"） 5、浙江东方乾睿贸易发展有限公司（简称"东方乾睿"） 6、浙江济桐贸易有限公司（简称"济桐贸易"） 7、浙江东方 ...

Core Viewpoint - Zhejiang Dongfang's stock price has shown volatility, with a year-to-date increase of 52.03%, but a recent decline of 2.11% on November 6, indicating potential market fluctuations and investor sentiment changes [1] Financial Performance - For the period from January to September 2025, Zhejiang Dongfang reported a revenue of 5.988 billion yuan, a year-on-year decrease of 39.66%, while the net profit attributable to shareholders was 800 million yuan, reflecting a significant year-on-year increase of 91.22% [2] - Cumulative cash dividends since the company's A-share listing amount to 2.287 billion yuan, with 745 million yuan distributed over the past three years [3] Shareholder and Market Activity - As of September 30, 2025, the number of shareholders decreased by 13.26% to 157,700, while the average circulating shares per person increased by 15.29% to 21,661 shares [2] - The stock has appeared on the trading leaderboard seven times this year, with the most recent instance on February 14, where it recorded a net buy of -28.9574 million yuan [1] Ownership Structure - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 21.045 million shares, an increase of 408,400 shares compared to the previous period [3] - Other notable shareholders include Southern CSI 1000 ETF and Huaxia CSI 1000 ETF, with slight reductions in their holdings [3]

Group 1 - The company announced the election of a new independent director, Chen Junze, following the resignation of the previous independent director, Li Bo, due to personal work reasons [1][2][3] - Chen Junze has extensive experience in the financial sector, having held various positions including Vice President at Zhejiang Equity Service Group and Chairman at Shanghai Yitong Investment Technology Co., Ltd. [3][4] - The board of directors approved the proposal to elect Chen Junze as an independent director and to adjust the membership of the specialized committees, which will take effect upon approval at the shareholders' meeting [1][2][3] Group 2 - The company’s subsidiary, Shanghai Wanzijian Biotechnology Co., Ltd., along with Healgen Scientific LLC, has recently obtained medical device registration certificates in China, Australia, and Singapore [5] - The newly registered products enhance the company's flow cytometry technology platform and expand the market for respiratory triple detection products internationally [5] - The company plans to hold its second extraordinary shareholders' meeting on November 20, 2025, to discuss the election of the new independent director and other matters [8][9][10]

Core Points - The company has elected Chen Junze as an independent director and adjusted the specialized committees within the board [1][2][3] - Chen Junze's qualifications and independence have been verified and approved by the Shanghai Stock Exchange [2][3] - The company has recently obtained medical device registration certificates for several products, enhancing its product offerings [3][5] Group 1: Board Changes - Independent director Li Bo resigned due to personal work reasons [1] - Chen Junze has been nominated as an independent director candidate and will serve on various committees upon shareholder approval [1][2] - The specialized committee members have been updated, with Chen Junze taking key roles [4] Group 2: Medical Device Registration - The company’s subsidiary has received medical device registration certificates in China, Australia, and Singapore [3][5] - The new products will expand the company's market reach and enhance its product variety [5] Group 3: Upcoming Shareholder Meeting - The second extraordinary general meeting of shareholders is scheduled for November 20, 2025 [6][10] - The meeting will utilize both on-site and online voting methods [6][8] - Shareholders must register in advance and provide necessary documentation to attend [9][10]